An Open Letter to Capitol Hill: From Fractured to Fractal Health Care Design
Why Health Policy Needs a Safe Harbor for Continuity To the Members of Congress, I am writing in response to recent reporting on President Donald Trump’s new health care proposal, including c...
When Analysis Paralysis Slows Healing—and Healthcare Reform
Why Progress Requires a Safe Harbor and a Clear First Step In a recent business article titled Digital Transformation in 2026: What to Modernize First for Maximum ROI, the authors make a simple bu...
Policy Gridlock and Moral Injury in Healthcare Workers
Need for a Safe Harbor Sometimes, strain in healthcare does not come from a single crisis.It comes from uncertainty that never resolves. In recent weeks, news coverage has focused on congressio...
Generic Medication Quality, Trust, and Readiness
What New Reporting Means for Patients Recent investigative reporting by ProPublica has raised important questions about how the U.S. Food and Drug Administration oversees the quality of generic me...
NIH Zero Embargo Policy: When Bureaucracy Stops Blocking Science
When Bureaucracy Becomes the Bottleneck (And When it Doesn’t) For years, one of the quiet frustrations in medicine has been this: Science can be sound, even world-class, and still arrive too ...
The ACA Stalemate: A Stereoscopic View from the Mountain Top
Where Freedom Meets Shared Responsibility This month’s U.S. health policy news reveals a familiar tension–how societies choose to care for people throughout predictable life stages, including ...
Quantum Opportunities: When Influence Goes Private
An AP Headline, a Life Vision, and My Mother's Letter to Paul Mellon In this season of Light, the Associated Press reported that MacKenzie Scott donated $7.1 billion to nonprofits in 2025, describ...
Congress, Obamacare, and the “Front Door” of Care
Wall Street Meets Sabai Sabai In this season of Light, we turn our attention to protecting care - because we can’t let the “Grinch” steal what people need most: timely access, trust, and com...
FDA Removes Black Box Warnings on Estrogen Products
The FDA Just Corrected Course. Now It's Time to Correct the Language On November 10, 2025, the U.S. Food and Drug Administration announced it will remove the boxed ("black box") warnings from most...
Hormone Therapy & Breast Cancer Risk: What It Means for Adolescents and Young Women with Primary Ovarian Insufficiency
Latest NIH Analysis Researchers at the National Institutes of Health (NIH) analyzed data from more than 459,000 women under age 55 and found that: Absolute risk by age 55: ~3.6% (E-HT users) v...
